tetano
Editor, Senior Moderator
Front Immunol
. 2021 Dec 23;12:808064.
doi: 10.3389/fimmu.2021.808064. eCollection 2021.
Global Perspectives on Immunization Against SARS-CoV-2 During Pregnancy and Priorities for Future Research: An International Consensus Paper From the World Association of Infectious Diseases and Immunological Disorders
Bahaa Abu-Raya[SUP] 1 [/SUP], Shabir A Madhi[SUP] 2 3 [/SUP], Saad B Omer[SUP] 4 5 [/SUP], Gayatri Amirthalingam[SUP] 6 [/SUP], Michelle L Giles[SUP] 7 8 [/SUP], Katie L Flanagan[SUP] 9 10 11 12 [/SUP], Petra Zimmermann[SUP] 13 14 [/SUP], Miguel O'Ryan[SUP] 15 [/SUP], Marco A Safadi[SUP] 16 [/SUP], Vassiliki Papaevangelou[SUP] 17 [/SUP], Kirsten Maertens[SUP] 18 [/SUP], Nasamon Wanlapakorn[SUP] 19 [/SUP], Vicens Diaz-Brito[SUP] 20 [/SUP], Eline Tommelein[SUP] 21 [/SUP], Susanna Esposito[SUP] 22 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pregnancy is associated with a higher risk for severe morbidity and mortality when compared with infection in non-pregnant women of childbearing age. An increasing number of countries recommend immunization against SARS-CoV-2 in pregnant women. Recent studies provide preliminary and supportive evidence on safety, immunogenicity and effectiveness of coronavirus disease 2019 (COVID-19) vaccines in pregnant women; however, important knowledge gaps remain which warrant further studies. This collaborative consensus paper provides a review of the current literature on COVID-19 vaccines in pregnant women, identifies knowledge gaps and outlines priorities for future research to optimize protection against SARS-CoV-2 in the pregnant women and their infants.
Keywords: COVID-19; SARS-CoV-2; maternal immunization; maternal vaccination program; pregnant women.
. 2021 Dec 23;12:808064.
doi: 10.3389/fimmu.2021.808064. eCollection 2021.
Global Perspectives on Immunization Against SARS-CoV-2 During Pregnancy and Priorities for Future Research: An International Consensus Paper From the World Association of Infectious Diseases and Immunological Disorders
Bahaa Abu-Raya[SUP] 1 [/SUP], Shabir A Madhi[SUP] 2 3 [/SUP], Saad B Omer[SUP] 4 5 [/SUP], Gayatri Amirthalingam[SUP] 6 [/SUP], Michelle L Giles[SUP] 7 8 [/SUP], Katie L Flanagan[SUP] 9 10 11 12 [/SUP], Petra Zimmermann[SUP] 13 14 [/SUP], Miguel O'Ryan[SUP] 15 [/SUP], Marco A Safadi[SUP] 16 [/SUP], Vassiliki Papaevangelou[SUP] 17 [/SUP], Kirsten Maertens[SUP] 18 [/SUP], Nasamon Wanlapakorn[SUP] 19 [/SUP], Vicens Diaz-Brito[SUP] 20 [/SUP], Eline Tommelein[SUP] 21 [/SUP], Susanna Esposito[SUP] 22 [/SUP]
Affiliations
- PMID: 35003137
- PMCID: PMC8733958
- DOI: 10.3389/fimmu.2021.808064
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pregnancy is associated with a higher risk for severe morbidity and mortality when compared with infection in non-pregnant women of childbearing age. An increasing number of countries recommend immunization against SARS-CoV-2 in pregnant women. Recent studies provide preliminary and supportive evidence on safety, immunogenicity and effectiveness of coronavirus disease 2019 (COVID-19) vaccines in pregnant women; however, important knowledge gaps remain which warrant further studies. This collaborative consensus paper provides a review of the current literature on COVID-19 vaccines in pregnant women, identifies knowledge gaps and outlines priorities for future research to optimize protection against SARS-CoV-2 in the pregnant women and their infants.
Keywords: COVID-19; SARS-CoV-2; maternal immunization; maternal vaccination program; pregnant women.